London, UK, 3rd December 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, today announces that the US Food and Drug…Original Article
Shield Therapeutics Announces the NDA for Feraccru has been Accepted for Filing and Review by FDA
